Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Sunnybrook Health Sciences Centre
Sponsor:
Collaborator:
Abbott
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT00420966
First received: January 10, 2007
Last updated: November 25, 2013
Last verified: November 2013
  Purpose

The purpose of this study is to determine the utilization patterns and compliance rates of palivizumab, which is a monoclonal antibody therapy used to prevent respiratory syncytial virus infection.


Condition Phase
Lower Respiratory Tract Infection
Respiratory Syncytial Virus Infections
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers

Resource links provided by NLM:


Further study details as provided by Sunnybrook Health Sciences Centre:

Primary Outcome Measures:
  • Determine palivizumab outcome measures [ Time Frame: Per respiratory syncytial virus season ] [ Designated as safety issue: No ]

    The objectives of this study are:

    • To determine palivizumab usage patterns, annually
    • To understand palivizumab infant demographics, including: potential neonatal, familial and environmental risk factors
    • To determine reasons for hospitalization, respiratory syncytial virus hospitalization rates, length of stay, morbidity and mortality
    • To determine intensive care unit admissions, length of stay, use of respiratory support (e.g., mechanical ventilation, CPAP) and complication rates
    • To determine compliance rates
    • To collect safety data


Estimated Enrollment: 1000
Study Start Date: October 2005
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Respiratory syncytial virus (RSV) is the most important viral respiratory pathogen in children. Infection due to RSV represents a large public health burden; in Canada, it accounts for 5,800 hospitalizations annually. The peak incidence of RSV disease occurs between 2-6 months of age with half of all infants infected in the first year of life. Palivizumab has been approved for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high-risk of RSV disease. These children include those born premature, those with bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD).

With the recent approval of palivizumab in Canada, access to this medication has increased. However, there are limited data on utilization, compliance, and health outcomes, particularly the frequency and severity of RSV infections. The primary objective of this study is to provide insight into the current management (utilization, compliance) of children at high-risk of RSV infection with palivizumab prophylaxis in the tertiary care centers and community settings through the development of a Canadian Registry Database.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Children who have received at least one dose of palivizumab.

Criteria

Inclusion Criteria:

  • All children who receive at least one dose of palivizumab

Exclusion Criteria:

  • The child's parent or legal guardian could not communicate in either English or French
  • The child had received palivizumab as part of a clinical trial during the study period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00420966

Contacts
Contact: Abby Li, MSc, CCRP 416-480-6100 ext 3185 abby.li@sunnybrook.ca
Contact: Krista L Lanctôt, PhD 416-480-6100 ext 2241 krista.lanctot@sunnybrook.ca

Locations
Canada, Alberta
Alberta Children's Hospital Recruiting
Calgary, Alberta, Canada, T3B 6A8
Contact       RSV.Calgary@calgaryhealthregion.ca   
Principal Investigator: Ian Mitchell, MB, FRCPC         
Canada, Ontario
McMaster Children's Hospital Recruiting
Hamilton, Ontario, Canada, L8N 3Z5
Contact: Susan Steele, RN       ssteele@mcmaster.ca   
Principal Investigator: Bosco Paes, MD, FRCPC         
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Abbott
Investigators
Principal Investigator: Ian Mitchell, MB, FRCPC University of Calgary
Study Director: Krista L Lanctôt, PhD Sunnybrook Health Sciences Centre
Study Director: Bosco Paes, MD, FRCPC McMaster University
  More Information

No publications provided by Sunnybrook Health Sciences Centre

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT00420966     History of Changes
Other Study ID Numbers: 456-2005
Study First Received: January 10, 2007
Last Updated: November 25, 2013
Health Authority: Canada: Health Canada

Keywords provided by Sunnybrook Health Sciences Centre:
lower respiratory tract infection
respiratory syncytial virus infections
palivizumab
outcomes
utilization
compliance

Additional relevant MeSH terms:
Respiratory Syncytial Virus Infections
Infection
Communicable Diseases
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 01, 2014